Dr. Marshall P. Stagg II, MD
Hematology & Oncology (Hematology & Oncology Physician)
8585 Picardy Ave, Suite 312
Baton Rouge, LA 70809
Who else practices at this address →
East Baton Rouge Parish includes primary care (46% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in New Orleans (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 86
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: Louisiana State University School of Medicine in New Orleans
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
LA license 019154
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Our Lady of the Lake Regional Medical Center Baton Rouge, LA
Medical groups
- Our Lady of the Lake Physician Group LLC (644 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 86
- Services billed
- 522
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 161 | 58 |
| Established patient office or other outpatient visit, 40-54 minutes | 114 | 28 |
| Established patient office or other outpatient visit, 20-29 minutes | 68 | 52 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Baton Rouge, LA | 97 |
| Oxycodone Hcl Other prescribers in Baton Rouge, LA | 55 |
| Revlimid (lenalidomide) | 39 |
| Ondansetron Hcl Other prescribers in Baton Rouge, LA | 34 |
| Dexamethasone Other prescribers in Baton Rouge, LA | 34 |
| Gabapentin Other prescribers in Baton Rouge, LA | 29 |
| Anastrozole Other prescribers in Baton Rouge, LA | 27 |
| Tramadol Hcl Other prescribers in Baton Rouge, LA | 26 |
| Olanzapine Other prescribers in Baton Rouge, LA | 26 |
| Xtandi (enzalutamide) | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 38 companies reported 154 payments worth $6,615 in total to this clinician.
| AbbVie Inc. | $1,653 |
|---|---|
| Novartis Pharmaceuticals Corporation | $1,294 |
| AstraZeneca Pharmaceuticals LP | $502 |
| Janssen Biotech, Inc. | $476 |
| Regeneron Pharmaceuticals, Inc. | $321 |
| Merck Sharp & Dohme LLC | $213 |
| Daiichi Sankyo Inc. | $184 |
| Astellas Pharma Global Development | $159 |
| Food and Beverage | $3,973 |
|---|---|
| Consulting Fee | $1,500 |
| Long term medical supply or device loan | $1,000 |
| Education | $142 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Nov 17, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $1,500 |
| Janssen Biotech, Inc. Jun 2, 2025 | Education DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind | $99.00 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
All 15 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| AstraZeneca Pharmaceuticals LP Nov 19, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
| AbbVie Inc. Nov 17, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $1,500 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Janssen Biotech, Inc. Jun 2, 2025 | Education DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind | $99.00 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 22 industry-funded studies in 2025, from 12 companies. The companies reported $490,331 in research payments for these studies, mostly to the institutions running them.
- An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Part…
Merck Sharp & Dohme LLC - A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB N2 NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platin…
Merck Sharp & Dohme LLC - A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refract…
Celgene Corporation - A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (…
Amgen Inc. - A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia
Novartis Pharmaceuticals Corporation - A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Karyopharm Therapeutics Inc. - A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvaluma…
Amgen Inc. - An Observational Multi-center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobiliary Cancers
AstraZeneca UK Limited - A Noninterventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Advanced or Metastatic Malignancies
Amgen Inc. - ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT05949684
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.